Fig. 3From: Safety and outcomes analysis: transcatheter implantation of autologous angiogenic cell precursors for the treatment of cardiomyopathyFlow diagram. Of the 74 consecutive patients undergoing review, 21 were excluded for incomplete documentation or LVEF > 50%.Back to article page